Erectile Dysfunction - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Erectile Dysfunction - Pipeline Review, H2 2016

Erectile Dysfunction - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Erectile Dysfunction - Pipeline Review, H2 2016
Published Jul 30, 2016
108 pages — Published Jul 30, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Erectile Dysfunction - Pipeline Review, H2 2016, provides an overview of the Erectile Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction
- The report reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects
- The report assesses Erectile Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Erectile Dysfunction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline

  
Source:
Document ID
GMDHC8314IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Erectile Dysfunction Overview101
Therapeutics Development112
  Pipeline Products for Erectile Dysfunction Overview111
  Pipeline Products for Erectile Dysfunction Comparative Analysis121
Erectile Dysfunction Therapeutics under Development by Companies132
Erectile Dysfunction Therapeutics under Investigation by Universities/Institutes151
Erectile Dysfunction Pipeline Products Glance164
  Late Stage Products161
  Clinical Stage Products171
  Early Stage Products181
  Unknown Stage Products191
Erectile Dysfunction Products under Development by Companies202
Erectile Dysfunction Products under Investigation by Universities/Institutes221
Erectile Dysfunction Companies Involved in Therapeutics Development2317
  Apricus Biosciences, Inc.231
  Aytu BioScience, Inc.241
  Biopharm GmbH251
  Futura Medical Plc261
  Hanmi Pharmaceuticals, Co. Ltd.271
  Humanetics Corporation281
  IntelGenx Corp.291
  Ion Channel Innovations, LLC301
  Mezzion Pharma Co. Ltd.311
  Mitsubishi Tanabe Pharma Corporation321
  Monosol Rx, LLC331
  NAL Pharmaceuticals Ltd.341
  Palatin Technologies, Inc.351
  Pharmicell Co., Ltd.361
  Sihuan Pharmaceutical Holdings Group Ltd.371
  Suda Ltd381
  Yungjin Pharm. Co., Ltd.391
Erectile Dysfunction Therapeutics Assessment4010
  Assessment by Monotherapy Products401
  Assessment by Combination Products411
  Assessment by Target422
  Assessment by Mechanism of Action442
  Assessment by Route of Administration462
  Assessment by Molecule Type482
Drug Profiles5043
  (PDE-5 Inhibitor + tramadol hydrochloride) Drug Profile501
  alprostadil Drug Profile516
  AP-102 Drug Profile571
  avanafil Drug Profile581
  BIO-300 Drug Profile593
  BL-214 Drug Profile621
  Cellgram-ED Drug Profile631
  fadanafil Drug Profile641
  HCP-1302 Drug Profile651
  HCP-1303 Drug Profile661
  MED-2002 Drug Profile672
  MED-2005 Drug Profile691
  Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction Drug Profile701
  pVAX-hSlo Drug Profile711
  Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease Drug Profile722
  sildenafil citrate Drug Profile741
  sildenafil citrate Drug Profile751
  sildenafil citrate Drug Profile761
  Small Molecule to Inhibit PDE5 for Erectile Dysfunction Drug Profile771
  SUD-003 Drug Profile782
  Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction Drug Profile801
  T-6932 Drug Profile811
  tadalafil Drug Profile821
  tadalafil Drug Profile831
  tadalafil Drug Profile841
  TF-0092 Drug Profile851
  TPN-729 Drug Profile861
  TR-399 Drug Profile871
  udenafil Drug Profile883
  VLFIA-330 Drug Profile911
  YBH-1603 Drug Profile921
Erectile Dysfunction Dormant Projects934
Erectile Dysfunction Discontinued Products971
Erectile Dysfunction Product Development Milestones989
  Featured News &Press Releases981
    Mar 28, 2016: MonoSol Rx Successfully Completes Pre-IND Meeting with the FDA for PharmFilm Tadalafil981
    Nov 25, 2015: iX Biopharma Announces Success Of Pilot Bioavailability Study For Pheonix981
    Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity991
    Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting991
    Nov 03, 2014: Auxilium Pharmaceuticals To Present STENDRA Data At SMSNA Scientific Meeting1001
    Sep 18, 2014: VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity1001
    Jul 09, 2014: New Grant Enables Humanetics to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients1011
    Apr 11, 2014: VIVUS To Present Clinical Data On Avanafil at European Association of Urology1021
    Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product1021
    Jan 21, 2014: VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil)1021
    Aug 01, 2013: VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil1031
    Jun 26, 2013: Vivus Announces European Approval For Spedra For Treatment Of Erectile Dysfunction1032
    Jun 19, 2013: Vivus Announces Positive Results From TA-501 Clinical Trial Of Stendra For Treatment Of Men With Erectile Dysfunction1051
    Apr 25, 2013: Vivus Receives CHMP Positive Opinion For Spedra For Treatment Of Erectile Dysfunction In Adult Men1061
    Jul 18, 2012: Zydus Urosciences Launches Udenafil For Treatment Of Erectile Dysfunction In India1061
Appendix1072
  Methodology1071
  Coverage1071
  Secondary Research1071
  Primary Research1071
  Expert Panel Validation1071
  Contact Us1071
  Disclaimer1081

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Erectile Dysfunction - Pipeline Review, H2 2016" Jul 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Erectile-Dysfunction-Pipeline-Review-H2-2016-2088-16304>
  
APA:
Global Markets Direct - Market Research. (2016). Erectile Dysfunction - Pipeline Review, H2 2016 Jul 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Erectile-Dysfunction-Pipeline-Review-H2-2016-2088-16304>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.